Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

consultant review.

Financial Results

The consolidated net loss for the year ended December 31, 2007 was $47.2 million or ($0.56) per share compared with a consolidated net loss of $40.9 million or ($0.62) per share for the previous year. The consolidated net loss for the fourth quarter ended December 31, 2007 was $11.7 million or ($0.13) per share compared with a consolidated net loss of $14.1 million or ($0.20) per share for the fourth quarter of the previous year.

Total consolidated expenses for the year ended December 31, 2007 were $48.0 million compared to $42.2 million for the previous year. Total consolidated expenses for the three months ended December 31, 2007 were $12.1 million compared to $14.4 million for the same quarter of the previous year.

Research and development expenses for the year ended December 31, 2007 totaled $38.9 million compared with $35.2 million in 2006. The increase was due primarily to the start up and initial enrollment of patients in the MAESTRO-02 follow-on trial, the full enrollment and continuation of the MINDSET-01 clinical trial and the start-up and commencement of enrolment of the MAESTRO-03 clinical trial. It is expected that research and development expenses will increase over the next two years as the current clinical trials for MBP8298; MAESTRO-01, MAESTRO-02, MAESTRO-03 and MINDSET-01, continue in Canada, Europe and the U.S.

Research and development expenses were $9.3 million for the fourth quarter ended December 31, 2007 compared to $12.5 million for the fourth quarter of the previous year. The reduction in expenses was the net result of reduced costs for the MAESTRO-01 trial, as more patients are completing or near completion of their two years on the trial, and a reduction in the number of batches of MBP8298 manufactured in the year, offset by start-up costs for the MAESTRO-02 and MAESTRO-03 trials.

General and administrative expenses were $7.5 million for the year ended December
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... trademark owners have been battling search engines and online ... that trigger online advertising. Two recent and conflicting rulings ... law to the new keyword technology can be a ... a recent court ruling on advertising triggered by the ...
... high gas costs and poor sport utility vehicle (SUV) ... at the University of Wisconsin-Madison has spent the last ... fuel-efficient SUVs in North America. The principles behind the ... incorporated into mass-production hybrid SUVs. , ,The effort is ...
... Wis. - Before Gov. Jim Doyle ... of stem cell research, a key Republican legislator had already ... projects. , ,The projects, which now are the subject of ... the Doyle Administration by State Sen. Ted Kanavas , ...
Cached Biology Technology:Keyword advertisers win some, lose some 2Keyword advertisers win some, lose some 3Keyword advertisers win some, lose some 4Keyword advertisers win some, lose some 5UW-Madison hybrid-vehicle team places second nationally 2GOP lawmaker faults Doyle for IT problems 2GOP lawmaker faults Doyle for IT problems 3
(Date:4/14/2014)... RICHLAND, Wash. Think of the pressure change you feel ... tall building. Imagine how you,d feel if that elevator carried ... Everest in the blink of an eye. , That,s ... the turbulent waters near a dam. For some, the change ... die or are seriously injured. , In an article in ...
(Date:4/14/2014)... collaborators have reconstructed the phylogeny and biological history for ... region of the Earth surrounding the equator. In-depth ... species new to science, each having previously been confused ... on this group began, Sturnira has grown ... were described in a new study, published online in ...
(Date:4/14/2014)... an animal stops to look around its environment, neuroscientists ... the birth of a memory. , Using lab ... neuroscience in the Zanvyl Krieger Mind/Brain Institute at Johns ... the rats frequently paused to inspect their environment with ... this behavior activated a place cell in their brain, ...
Breaking Biology News(10 mins):Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3Neuroscientists: Brain activity may mark the beginning of memories 2Neuroscientists: Brain activity may mark the beginning of memories 3
... years of exhaustive analysis led by a University of Alberta ... exploded from just a handful to more than 4,000. ... ailing patient looks at something like 10 to 20 chemicals," ... blood chemicals that doctors can potentially look at to diagnose ...
... 24, 2011 For a week in March, the permanent ... and other attractions becomes the world capital of science as ... 241st National Meeting & Exposition of the American Chemical Society ... world,s largest scientific society, and the sessions in balmy Anaheim ...
... identified a strain of probiotic bacteria that may be useful ... They report their findings in the February 2011 issue of ... H. pylori is considered one of the major risk ... ulcers," write the researchers. "Currently, antibiotic-based treatment for ...
Cached Biology News:Researcher lists more than 4,000 components of blood chemistry 2American Chemical Society National Meeting & Exposition, March 27-31, Anaheim, Calif. 2Probiotic identified to treat ulcers 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: